FORMUTECH 2025
Milan, Italy

14 — 15 October 2025
Sheraton Milan San Siro

mRNA Process Development
& Manufacturing | LNP Formulations

FORMUTECH

SILVER SPONSORS

ATEM STRUCTURAL DISCOVERY

SARTORIUS

INPROCESS | LSP

Quantum Biosciences

Corden Pharma

MEDIA PARTNERS

BioPharma Asia

Bio-Equip www.bio-equip.cn

Bio Pharma Trend

Gene Therapy Net
www.genetherapynet.com
- Breaking News
- Conferences
- Clinical Trials
- Viral Vectors
- Legislation
- Societies

KC World With Science www.kindcongress.com

Medhealth Outlook

LAB WORLD

PHARMA network magazine

The FormuTech Summit 2025, taking place in Milan on October 14–15, is a premier industry event focused on mRNA process development and LNP formulation. Designed for biotech, pharma, and regulatory professionals, the summit brings together global leaders to explore the end-to-end journey of RNA therapeutics — from IVT template synthesis to cGMP-scale LNP manufacturing. The agenda features 20+ expert talks and two panel discussions, covering key challenges such as potency optimization, thermostable formulations, analytical and QC strategies, and regulatory alignment. This year's program also addresses emerging concerns like LNP-associated toxicity in repeated dosing and green, cost-effective platforms for scalable production. Attendees will gain actionable insights, forge high-level partnerships, and discover practical innovations driving the next generation of RNA medicines.

Learn The Key Practical Points

1. Scalable Manufacturing Platforms
Learn how modular and integrated systems like "mRNA Manufacturing-in-a-Box" are enabling cost-effective, GMP-compliant production at clinical and commercial scales.

2. Optimizing RNA Release Timelines
Discover strategies for accelerating clinical material readiness through platform-based process optimization and rapid development frameworks.

3. Enhancing LNP Potency and Efficiency
Explore cutting-edge lipid design and formulation methods that can boost LNP delivery potency by up to 1000X.

4. Achieving Thermostability for RNA Therapeutics
Understand emerging technologies that allow RNA-LNP products to remain stable at elevated temperatures for global access and distribution.

5. Safety in Repeated Dosing: Overcoming LNP Toxicity
Address one of the industry's top concerns: immunogenicity and toxicity associated with repeated or long-term LNP administration.

6. Advanced Analytical & QC Methodologies
Gain insight into modular, regulatory-ready analytical toolkits that ensure product consistency and quality from early R&D through to GMP.

7. IVT Innovations & Template Optimization
Learn about advancements in synthetic DNA templates, dsRNA reduction, and high-yield IVT processes for translational research.

8. Integrated CMC and Regulatory Strategies
Understand how to align technical operations with evolving regulatory expectations, particularly for complex nanomedicines.

9. End-to-End GMP Manufacturing from pDNA to LNP

Dive into process workflows that span multiple payload types and support scale-up without compromising quality.

10. Foresight into Emerging RNA-LNP Modalities

Preview future trends such as combination mRNA products, adaptive LNP systems, and next-gen delivery innovations under development today.

EPM Group Executive Summary

WHO You Will Meet

50+
Attendees

20+
Speakers

RATIO

Bio/pharmaceutical manufacturing **65:35** Vendor/Solution Providers

Company Size of Attendees



- 1000+ employees
- 300-999 employees
- 50-299 employees
- less than 49 employees

Job Title of Attendees



- C-level
- SVP/VP
- Snr Director/Director
- Snr Manager/Manager

Attendee Company Annual Turnover



- 1 Billion
- $500-999Million
- $50-499 Million
- <50 Million

HOW You Will Benefit

x1000+

Relive the conference full Acess to documentation, footages and videos.

x10+

Hours of Networking forge new professional contacts.

x20+

Case Studies Analisys

Companies Attending Our Events

FEEDBACK

94%

RATED EVENT

★★★★★

Quality of the speakers
Sharing of the best practices
Spectrum of industries
Intimate atmosphere

98%

WOULD RECOMMEND THE EVENT TO COLLEAGUES

Meet The Speakers

Viktoria Enkmann

CEO at RNAnalytics

Chiara Bruckmann

Lab Head, mRNA Process, Formulation an Analytical Development group at ThermoFisher

Bojan Kopilovic

Postdoctoral Research Associate at University of Sheffield

Ad Gerich

CEO/Managing Director at InProcess-LSP

Rongjun Chen

Head of the Biomaterials and Nanomedicine Laboratory at Imperial College London

Maria Colombo

Director R&D Nucleic Acid Services at Thermo Fisher Scientific



Aleš Štrancar

Managing Co-Director at Sartorius BIA Separations

Serra Gürcan

Subject Matter Expert at Corden Pharma

Harris Makatsoris

Founder at Centillion Technology Limited

Andrew Varley

Director; RNA & Formulation Core at University of British Columbia

Davide De Lucrezia

Vice President & General Manager at Officinae Bio, part of Maravai LifeSciences

Pauline Urquia

R&D in vivo Project Manager at Sartorius Polyplus

Eike F. Joest

Head of Innovation mRNA Manufacturing at Merck KGaA

Carolin Thiele-Süß

Senior scientist at CureVac AG

Juliana Haggerty

Head of Centre of Excellence - LNP at CPI

Hui Liu

CEO at PrimaLux

Youlia Serikova

Senior Manager, RNA Research and Process Development at Quantoom Biosciences

Alexander Schwenger

Director LNP Process Development & AD/PD Coordination at Lonza

Ka-Wai Wan

Leading Senior Pharmaceutical Assessor at MHRA (Medicines and Healthcare products Regulatory Agency)

Karl Bertram

Co-founder | Managing Director at ATEM Structural Discovery

Scientific Agenda

DAY 0 MONDAY, OCTOBER 13

18:00 - 20:00	Pre-Conference Cocktail Reception at Silene Bar, SheratonMilan San Siro

DAY 1 TUESDAY, OCTOBER 14

8:30 - 9:00	FormuTech Summit: Registration

Morning Chairperson:
Chiara Bruckmann, Thermo Fisher

Session 1: Scalable Manufacturing Platforms for mRNA-LNP

9:00 - 9:30	mRNA-LNP Manufacturing-in-a-Box: Scalable, Low-Cost, and High-Quality Production **Bojan Kopilovic, Postdoctoral Research Associate at University of Sheffield**
9:30 - 10:00	Non-Viral Formulations ScaleUp and Manufacturing Strategies **Serra Gürcan, Subject Matter Expert at Corden Pharma**
10:00 - 10:30	Speed Networking
10:30 - 11:00	Morning Coffee Break
11:00 - 11:30	Rapid Development Framework: Accelerating mRNA from Sequence to Drug Substance **Maria Colombo, Director R&D Nucleic Acid Services, Thermo Fisher**

Session 2: Formulation Innovation & LNP Platform Engineering

11:30 - 12:00	How to Improve LNP Formulation Potency by 1000X **Hui Liu, CEO, PrimaLux**
12:00 - 12:30	Greener, Faster, Smarter: Transforming RNA-LNP Design and Manufacture for the Future **Juliana Haggerty, Head of Centre of Excellence – LNP, CPI**
12:30 - 13:00	Combining AI Powered mRNA Design with Innovative Non-Viral Delivery Solution for Organ Specific Targeting **Pauline Urquia, R&D in vivo Project Manager at Sartorius Polyplus & Davide De Lucrezia, Vice President & General Manager at Officinae Bio, part of Maravai LifeSciences**
13:00 - 14:00	Lunch Break

Afternoon Chairperson:
Alexander Schwenger, Lonza

Session 3: Analytical Technologies for LNP Characterization

14:00 - 14:30	Next-Gen Cryo-EM Based LNP Characterization **Karl Bertram, Co-founder | Managing Director at ATEM Structural Discovery**
14:30 - 15:00	The Next Level in LNP Size Characterization: Efficient and Non-Destructive Analysis with Spatially Resolved DLS **Ad Gerich, CEO/Managing Director at InProcess-LSP**

15:00 - 15:30	CureVac's tailored LNP platform to deliver mRNA for prophylactic and therapeutic applications **Carolin Thiele-Süß, Senior scientist at CureVac AG**
15:30 - 16:00	Afternoon Coffee Break
16:00 - 17:00	**Panel Discussion:** Building End-to-End mRNA-LNP Platforms How to Deliver Efficient, Scalable and Regulatory-Ready mRNA-LNP Therapies • Integration of modular technologies from DNA template to LNP delivery • Ensuring analytical robustness and QC scalability for clinical and commercial supply • Balancing cost, speed, and regulatory readiness **Panelists:** • Juliana Haggerty (CPI) • Chiara Bruckmann (Thermo Fisher) • Hui Liu (PrimaLux) • Rongjun Chen, Imperial College London • Carolin Thiele-Süß, CureVac Moderator by Alexander Schwenger (Lonza)
17:00	**End of FormuTech Summit** **1st day**
19:30 - 21:30	FormuTech Conference Dinner at El Patio del Gaucho by Javier Zanetti (Sheraton Hotel San Siro)

DAY 2 WEDNESDAY, OCTOBER 15

8:00 - 8:30	FormuTech Summit: Registration

Morning Chairperson:
Juliana Haggerty, CPI

Session 4: Analytical Strategies for RNA Process Development & QC

8:30 - 9:00	Analytical Methods in mRNA Manufacturing **Chiara Bruckmann, Lab Head, mRNA Process, Formulation and Analytical Development group at ThermoFisher**
9:00 - 9:30	Regulatory-Ready QC for LNPs: Bridging Analytical Gaps with Modular Toolkits & SaaS Integration **Viktoria Enkmann, CEO at RNAnalytics**
9:30 - 10:00	Use of Synthetic DNA Templates, dsRNA Reduction Strategies During IVT, and Associated Analytical Technologies **Eike F. Joest, Head of Innovation mRNA Manufacturing at Merck KGaA**

Session 5: Industrializing RNA: cGMP, Compliance & Scale-Up

10:00 - 10:30	The benefits of scale-out over scale-up : challenges and opportunities in a post-pandemic world **Youlia Serikova, Senior Manager, RNA Research and Process Development**
10:30 - 11:00	**Morning Coffee Break**
11:00 - 11:30	End-to-End GMP Innovation: Unlocking the Future of Complex RNA Therapeutics **Alexander Schwenger, Director LNP Process Development & AD/PD Coordination**

11:30 - 12:00	Is Regulation a Barrier for Nanomedicines Development? **Ka-Wai Wan, Senior Pharmaceutical Assessor, MHRA**
12:00 - 12:30	cGMP Manufacturing from pDNA to LNP with Multiple Payloads **Aleš Štrancar, Co-Director, Sartorius BIA Separations**
12:30 - 13:00	The BiaB™: A scale independent GMP-ready industrialised platform for DNA to xRNA™-LNP end-to-end manufacture **Harris Makatsoris, Founder at Centillion Technology Limited**
13:00 - 14:00	Lunch Break

Afternoon Chairperson:
Eike Joest, Merck KGaA

Session 6: IVT Process & Academic Leadership

14:00 - 14:30	Manufacturing IVT RNA for Translational Research **Andrew Varley, Director, University of British Columbia**
14:30 - 15:00	Groundbreaking LNP Technologies for Thermostable RNA Formulations **Prof. Rongjun Chen, Imperial College London**
15:00 - 16:00	**Panel Discussion:** Regulation, Readiness, and Risk in RNA Therapies From Bench to Market: Addressing Regulatory Complexities in mRNA and LNPs • Regulatory blind spots in LNP scale-up and IVT consistency • Software and digital solutions in GMP-readiness • Regulatory expectations for next-gen LNP payloads and thermostability claims **Panelists:** • Alexander Schwenger (Lonza) • Viktoria Enkmann (RNAnalytics) • Aleš Štrancar, Sartorius BIA Separations • Ka-Wai Wan, MHRA • Maria Colombo, Thermo Fisher Scientific Moderator by Eike F. Joest, Merck KGaA
16:00	Closing Remarks & End of the FormuTech Summit 2025




il Salotto
RISTORANTE - PIZZA - CAFFE' - WINE

Biographies

Alexander Schwenger Director LNP Process Development & AD/PD Coordination at Lonza

Alexander brings over a decade of experience in mRNA and LNP technologies, gained across both academia and the pharmaceutical industry. After earning his Diploma degree, he specialized in nucleic acid chemistry and nanostructuring, completing his PhD at the University of Stuttgart. Throughout his career, he has worked extensively with complex nucleic acid modalities and built a strong scientific track record with numerous publications. At CureVac SE in Germany, he held roles of increasing responsibility, contributing to the advancement of RNA-based therapeutics. Since June 2023, Alexander has been leading process development for nucleic acid delivery systems at Lonza in the Netherlands, and since 2024 he has also been coordinating the entire AD&PD area. In these roles, he is committed to driving innovation and advancing nucleic acid delivery to the next level.

Viktoria Enkmann CEO at RNAnalytics

Viktoria Enkmann is CEO and co-founder of RNAnalytics, developing toolkits and software for LNP analytics in RNA therapeutics. With a background in biomedicine and analytical chemistry, she has over 10 years of industry experience. She previously held roles at Sciex and Vela Labs, focusing on CE and MS technologies. Viktoria holds an MBA and multiple science degrees. She is recognized for bridging lab innovation with scalable biotech solutions.

Chiara Bruckmann Lab Head, mRNA Process, Formulation and Analytical Development Group at ThermoFisher

Chiara Bruckmann has over 20 years of experience in the field of life sciences and possesses strong expertise in downstream processes. She specializes in developing analytical tools and techniques that aid in understanding complex protein-nucleic acid systems. Her previous experience includes working in the R&D pre-clinical division of a small Italian biotech company where she contributed to moving the company's lead candidate into the clinical phase. Her educational background includes a BS in Biology, an MS in Biochemistry from the University of Rome (Italy), and a PhD in Structural Biology from the University of Edinburgh (UK).

Bojan Kopilovic Postdoctoral Research Associate at University of Sheffield

Dr Bojan Kopilovic is a bioengineer with a PhD in mRNA delivery systems from the University of Aveiro, Portugal. He is currently a Postdoctoral Research Associate at the University of Sheffield, working in collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) on the development of scalable, modular mRNA manufacturing platforms. With a PhD in Chemical Engineering and graduate studies in Chemistry, his research spans lipid nanoparticle (LNP) manufacturing process optimisation including lipid composition, mixer design evaluation, and orthogonal characterisation techniques for LNP stability and quality. Bojan is also involved in the computational modelling of LNP self-assembly kinetics as part of the RNABox™ Quality by Digital Design initiative, aiming to accelerate digital process development in RNA manufacturing.

Ad Gerich CEO/Managing Director at InProcess-LSP

Ad Gerich holds an academic degree in Analytical Chemistry and Chemometrics. He began his career in 1990 as a spectroscopist in the food and feed industry before moving into the pharmaceutical sector in 1998. Over the years, he held various positions at Organon and Schering-Plough, ultimately serving as Director of Product Development and Process Analytical Technology at Merck (The Netherlands). In 2014, Ad co-founded InProcess-LSP, an innovative company dedicated to Process Analytical Technology (PAT), with a strong emphasis on non-destructive, real-time nanoparticle size analysis. As CEO, he is primarily responsible for business development, strategic direction, and overall management, ensuring the company continues to pioneer cutting-edge PAT solutions for the life sciences industry.

Rongjun Chen Head of the Biomaterials and Nanomedicine Laboratory at Imperial College London

Rongjun Chen obtained his PhD degree and did his postdoctoral work in the Department of Chemical Engineering and Biotechnology at the University of Cambridge. He is Currently Professor of Biomaterials Engineering and Head of the Biomaterials and Nanomedicine Laboratory in the Department of Chemical Engineering at Imperial College London. His research focuses on design, synthesis and manufacturing of polymers, lipids and bio-inspired nanoparticles for targeted delivery of active pharmaceutical agents including RNA. He has developed a translational research programme on targeted nanomedicine, thermostable vaccine formulation, cell and gene therapy. His research work has been recognised by various awards including the IChemE Global Team Award in 2021, Imperial College President's Award for Outstanding Research Team in 2021, and highly commended for IChemE Global Biotechnology Award in 2018. He is an Editor for Chemical Engineering Journal (Elsevier) and an Editorial Board Member of Discover Molecules (Spinger Nature) and Nano Trends (Elsevier).

Maria Colombo Director R&D Nucleic Acid Services at Thermo Fisher Scientific

Maria Colombo has over 20 years of experience in life sciences, biotechnology, and bioprocessing. Since 2021, she has been serving as Director of R&D, Nucleic Acid Services within the Pharma Services Group at Thermo Fisher Scientific. She leads activities related to the development of nucleic acids used in the production of viral vectors, modified cell-based therapies, and mRNA-based vaccines and therapeutics. Previously, she worked at Kaneka Eurogentec, where she focused on addressing the needs in mRNA production and analysis, and contributed to the implementation of a C(D)MO service offering. Prior to that, she served as R&D Project Leader at Unisensor, where she developed diagnostic kits for the agri-food industry using lateral flow and flow cytometry technologies. She holds a Ph.D. in Sciences and a Master's in Biochemistry from the University of Liège, where she also completed a postdoctoral fellowship. She further pursued postdoctoral research at the University Hospital of Maastricht.

Aleš Štrancar Managing Co-Director at Sartorius BIA Separations

Aleš Štrancar has been the Executive Managing Director of Sartorius BIA Separations since its founding in 1998. He is a key inventor of the CIM Convective Interaction Media® monolithic columns technology and has co-invented numerous analytical methods for pDNA, mRNA, AAV, Adeno, and other viruses. Aleš has co-developed several downstream processing (DSP) processes, including pDNA for Boehringer Ingelheim and AAV for AveXis/Novartis. He is the author or co-author of over 100 scientific papers focused on separation and purification technologies and holds several granted patents.

Serra Gürcan Subject Matter Expert at Corden Pharma

Serra holds both a doctoral degree and a master's in pharmaceutical technology. In 2015, Serra began her research journey at the University of Pavia, focusing on polymeric micelles to enhance the solubility of hydrophobic payloads. She then advanced to complete her doctoral research at the University of Paris Saclay in 2020, where she concentrated on developing a combined therapy utilizing cationic solid lipid nanoparticles complexed with anti-TNF alpha siRNA and an anti-inflammatory drug.
In 2021, she joined Cytiva (formerly known as Precision NanoSystems) as a Field Application Scientist in the Nanomedicine Unit, where she offered consultations on drug product production and lipid nanoparticles, particularly RNA-loaded LNPs. As of June 2024, Serra has taken on the role of Associate Director of Lipid and LNP Platform at CordenPharma, where she supports nanomedicine and lipid manufacturing services from a technical standpoint, both commercial and communication perspectives.

Harris Makatsoris Founder at Centillion Technology Limited

Harris is the founder and director of Centillion Technology Limited, based in Cambridge, UK, a biotech specialising in the rapid scaling and manufacture of RNA-based therapeutics and vaccines, He is also Professor in the Department of Engineering at King's College London. He has a process engineering background with 28-years experience in both industry and academia. In all his past and present roles, he is managing interdisciplinary projects that require integration and coordination. Harris is an expert in continuous RNA manufacturing. His work is focusing on addressing the challenges in the rapid design, development and scalable manufacture of RNA and other nucleic acids and has pioneered the application of flow technologies in RNA manufacture, of various types. His research has attracted over £26m and he is currently leading a unique multi-disciplinary, multi-million pound programme comprising both industry and academia, building the Biofoundry-in-a-Box (BiaB). The BiaB is a unique portable, multi purpose RNA microfactory designed for the rapid design and deployment of a range of therapeutics and vaccines, with Low and Middle Income Countries in mind.

Andrew Varley Director; RNA & Formulation Core at University of British Columbia

Andrew Varley directs development of mRNA, saRNA, and circular RNA synthesis, purification, and analysis within the RNA & Formulation Core at UBC. He completed his post-doctoral training in translational medicine at the University of Toronto with Prof. Bowen Li and holds a PhD in Bio-organic Chemistry from Ontario Tech University. He has received numerous awards, including the NSERC Postdoctoral Fellowship and has been published in several journals including Nature Biotechnology and Advanced Materials. Andrew also contributes to national and international RNA centric organizations in science and community outreach.

Davide De Lucrezia Vice President & General Manager at Officinae Bio, part of Maravai LifeSciences

Davide is a synthetic biologist by training with a passion for bridging biology and computer science. He is co-founder and General Manager of Officinae Bio, now part of Maravai Life Sciences. Over the years, he has led multiple biotech ventures, focusing on innovation at the intersection between artificial intelligence and synthetic biology. His mission is to empower biologists to reprogram biology through smarter tools and streamlined workflows.

Pauline Urquia R&D in vivo Project Manager at Sartorius Polyplus

Pauline Urquia serves as the R&D in vivo Project Manager at Sartorius Polyplus. She has a Master's degree in Cellular Biology and her previous experience includes working in immuno-oncology with Eric Tartour's team at PARCC in Paris, where she researched the effects of vaccines on resident memory T lymphocytes in the lungs of mice. Additionally, she spent two years at Domain Therapeutics, focusing on the development of antibody-based and small molecule immunotherapies. Currently at Sartorius Polyplus, Pauline is responsible for overseeing the in vivo evaluation of innovative lipids aimed at generating lipid-based particles for in vivo applications.

Eike F. Joest Head of Innovation mRNA Manufacturing at Merck KGaA

Eike is Principal Scientist for innovations and technologies in mRNA service offering. He was responsible for development of the upscaled mRNA manufacturing process and implementation of AmpTec™ technologies in R&D. Before joining Merck Life Science KGaA in Darmstadt, Germany, he demonstrated broad technical expertise in synthetic biology and molecular biology by publishing in several peer-reviewed journals. Eike holds a M.Sc. with distinction in Biochemistry from Wuerzburg University and a summa cum laude Ph.D. in cellular Biochemistry from Frankfurt University.

Carolin Thiele-Süß Senior scientist at CureVac AG

Dr. Carolin Thiele-Süß is a senior scientist at CureVac AG in Tübingen, Germany, where she focuses on the development of mRNA-based therapeutics. Carolin has contributed to several innovative projects in the field of mRNA technology. She holds a PhD in Organic Chemistry from Saarland University, with a research background in synthetic methodologies and pharmaceutical applications. Prior to joining CureVac, she conducted research at the Helmholtz Institute for Pharmaceutical Research Saarland, further strengthening her expertise in translational science and drug development. Her work has been published in peer-reviewed journals and she is a named inventor on multiple patents. Her interdisciplinary approach bridges organic chemistry, molecular biology, and therapeutic innovation.

Juliana Haggerty Head of Centre of Excellence - LNP at CPI

Juliana (Jules) Haggerty is leading a new UK Centre of Excellence to enable radical innovation in the field of Intracellular Drug Delivery for nucleic acid therapies and vaccines, working with partners across the UK's academic and research ecosystem. She has worked at CPI since 2014, supporting their RNA vaccine programmes for the UK Vaccine Taskforce in 2020 and providing expert advice and due diligence on legacy activities and onshoring throughout 2021. Jules sits on the Technology and Innovation committee of the UK Medicines Manufacturing Industry Partnership and has significant expertise in the use of public/ private funding and collaborative R&D models to advance technology and innovation. In her early career, she spent 8 years at global Life Sciences company, Millipore, working on advanced technology development and best practice for biopharmaceutical manufacture and further developed expertise in image analysis, machine learning and algorithm development during her doctoral studies.

Hui Liu CEO at PrimaLux

Dr. Liu is the Founder and CEO of PrimaLux, a consulting firm specializing in pharmaceutical development. With over two decades of experience, Dr. Liu is an expert in formulating small molecules, RNAs, biologics, and gene therapies. He served as the Chief Technology Officer at Matinas Biopharma from 2020 to 2024. Prior to that, he was the Head of Formulation and Delivery at Seqirus, a global leader in influenza and pandemic response, where he spearheaded the development of lipid nanoparticle technology platforms for next-generation gene therapies. Earlier in his career, Dr. Liu held key roles at Cellics Therapeutics, Alcon (a Novartis spinoff), and Allergan (now part of AbbVie). He is a named inventor on 20 patents related to drug delivery technologies and biodegradable polymers. Dr. Liu holds a Ph.D. in Polymer Chemistry from the University of Michigan, an M.B.A. from the University of Massachusetts Amherst, and a B.S. from the University of Science and Technology of China.

Youlia Serikova Senior Manager, RNA Research and Process Development at Quantoom Biosciences

Graduated from UCLouvain (Belgium), Youlia Serikova holds a PhD in Cell Biology and Biochemistry and has more than 10 years of industrial experience in biotechnology and bioprocessing related to cell, viral and molecular biology. She leads development of capabilities in design and production of RNA-based medicines at Quantoom Biosciences.



Ka-Wai Wan Leading Senior Pharmaceutical Assessor at MHRA (Medicines and Healthcare products Regulatory Agency)

Dr Ka-Wai Wan is a pharmacist by training and graduated from The School of Pharmacy (University of London). She was trained as a hospital pharmacist before completing her PhD in nanomedicine at the Welsh School of Pharmacy (Cardiff, UK). Ka-Wai worked as an academic for over a decade and she was a Principal Lecturer in Pharmaceutics and Course Leader for the MSc Industrial Pharmaceutics from the School of Pharmacy and Biomedical Sciences at the University of Central Lancashire (UCLan, Preston) before moving to work at the Medicines and Healthcare products Regulatory Agency (MHRA) in 2016. She is now a Senior Pharmaceutical Assessor at the MHRA, leading on the assessment of nano-based medicinal products, and providing scientific advice on innovative medicines, particularly on nanomaterials used for both small and macromolecules delivery.

Karl Bertram Co-founder | Managing Director at ATEM Structural Discovery

Karl Bertram, PhD is a cryo-electron microscopy (cryo-EM) scientist, entrepreneur, and technology enthusiast dedicated towards advancing cryo-EM technology for industrial applications. As the Co-founder and Managing Director of ATEM Structural Discovery, he holds a PhD in biochemistry and structural biology and has an extensive scientific background in advanced cryo-EM technology. Karl obtained his PhD at the Max Planck Institute for Biophysical Chemistry in Göttingen, Germany, where he significantly contributed towards solving the first high-resolution 3D structures of the human spliceosome. During his academic career, he obtained a Master of Science degree in Biochemistry from the Ludwig Maximilian University (LMU) Munich and was a researcher at the Rockefeller University in New York City.


ICBC
FERMIAMO IL RIARMO
Donald's


SHERATON

SHERATON MILAN SAN SIRO

The FormuTech Summit 2025 will be held at the Sheraton Milan San Siro, a contemporary 4-star hotel located in one of the greenest and most residential areas of Milan. With its tranquil surroundings and modern design, the hotel offers the perfect balance between accessibility and exclusivity — ideal for high-level scientific and industry gatherings.

The hotel features elegant and versatile meeting facilities with natural daylight, an outdoor garden area perfect for networking events, and exceptional culinary experiences including the renowned El Patio del Gaucho, inspired by Argentinian tradition. Delegates will also enjoy access to a wellness centre, outdoor pool, and spacious guest rooms designed for comfort and relaxation.

Whether you're attending cutting-edge sessions or joining evening receptions, Sheraton Milan San Siro provides a stylish and welcoming setting for meaningful connections and knowledge exchange.



VIA CALDERA, 3, 20153
MILANO MI, ITALY